| 000 | 03752naa a22006257i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-050 | ||
| 003 | local | ||
| 005 | 20261005174905.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2020 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1007/s00428-020-02928-z _2doi |
|
| 035 | _a(local)EuropePMC:PMC7550230 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aK Dufraing _eauthor. |
|
| 245 | 1 | 0 |
_aBiomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. / _cK Dufraing; F Fenizia; E Torlakovic [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _b[publisher not identified], _c2020. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aIn personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation in external quality assurance (EQA) programs. Several providers offer predictive EQA programs for different cancer types, test methods, and sample types. In 2013, a guideline was published on the requirements for organizing high-quality EQA programs in molecular pathology. Now, after six years, steps were taken to further harmonize these EQA programs as an initiative by IQNPath ABSL, an umbrella organization founded by various EQA providers. This revision is based on current knowledge, adds recommendations for programs developed for predictive biomarkers by in situ methodologies (immunohistochemistry and in situ hybridization), and emphasized transparency and an evidence-based approach. In addition, this updated version also has the aim to give an overview of current practices from various EQA providers. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttp://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 650 | 4 | _aImmunohistochemistry | |
| 650 | 4 | _aGuideline | |
| 650 | 4 | _aOncology | |
| 650 | 4 | _ain situ Hybridization | |
| 650 | 4 | _aMolecular Pathology | |
| 650 | 4 | _aProficiency Testing | |
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _alaboratory quality | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aF Fenizia _eauthor. |
|
| 700 | 0 |
_aE Torlakovic _eauthor. |
|
| 700 | 0 |
_aN Wolstenholme _eauthor. |
|
| 700 | 0 |
_aZ C Deans _eauthor. |
|
| 700 | 0 |
_aE Rouleau _eauthor. |
|
| 700 | 0 |
_aM Vyberg _eauthor. |
|
| 700 | 0 |
_aS Parry _eauthor. |
|
| 700 | 0 |
_aE Schuuring _eauthor. |
|
| 700 | 0 |
_aElisabeth M C Dequeker _eauthor. |
|
| 700 | 0 |
_a _eauthor. |
|
| 773 | 0 |
_tVirchows Archiv : an international journal of pathology _gVol. 478, no. 3, (2020), pages/article 553-565 _x0945-6317 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC7550230 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC7550230 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1192 _d1192 |
||